help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holdaway, I. M.
Right arrow Articles by Ibbertson, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holdaway, I. M.
Right arrow Articles by Ibbertson, H. K.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 608-613, Copyright © 1984 by Endocrine Society

ARTICLES

Low thyroxine levels in some hyperprolactinemic patients due to dopaminergic suppression of thyrotropin

IM Holdaway, MC Evans, A Sheehan and HK Ibbertson

The serum free T4 index (FT4I) was at or below the lower limit of normal in 8 of 55 unselected patients with hyperprolactinemia. Serum levels of T3 were normal and none of the patients had clinical evidence of hypothyroidism. In patients with low FT4I the serum TSH was within the normal range and TSH was released normally after administration of TRH, indicating normal pituitary TSH reserve. Serum TSH also increased after administration of the dopamine antagonist domperidone. The TSH response to domperidone was significantly greater in the hyperprolactinemic group with low FT4I compared with either normal subjects or hyperprolactinemic patients with normal FT4I, suggesting that depression of FT4I was due to increased dopaminergic activity. Administration of the dopamine antagonist metoclopramide for 4 days led to a supranormal rise in FT4I in 3 of 5 patients with low FT4I. Thus, a minority of hyperprolactinemic patients have a low FT4I which appears due to excessive hypothalamic production of dopamine.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society